| Literature DB >> 32733882 |
Anny W Robert1, Bruna H Marcon1, Bruno Dallagiovanna1, Patrícia Shigunov1.
Abstract
Adipogenesis, osteogenesis and chondrogenesis of human mesenchymal stem/stromal cells (MSC) are complex and highly regulated processes. Over the years, several studies have focused on understanding the mechanisms involved in the MSC commitment to the osteogenic, adipogenic and/or chondrogenic phenotypes. High-throughput methodologies have been used to investigate the gene expression profile during differentiation. Association of data analysis of mRNAs, microRNAs, circular RNAs and long non-coding RNAs, obtained at different time points over these processes, are important to depict the complexity of differentiation. This review will discuss the results that were highlighted in transcriptome analyses of MSC undergoing adipogenic, osteogenic and chondrogenic differentiation. The focus is to shed light on key molecules, main signaling pathways and biological processes related to different time points of adipogenesis, osteogenesis and chondrogenesis.Entities:
Keywords: adipogenesis; cell differentiation; chondrogenesis; gene expression profile; mesenchymal stem/stromal cell; osteogenesis; transcriptome
Year: 2020 PMID: 32733882 PMCID: PMC7362937 DOI: 10.3389/fcell.2020.00561
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
Summary of transcriptome studies that analyzed adipogenic and/or osteogenic differentiation of MSC.
| MSC tissue source (surgical procedure, donor age) | Immuno-phenotype (% of positive cells) | Time points | Induction media | RNA type isolated for analysis | Method (platform) | References |
| CD73+ | 1, 7, 14, 21 | DMEM; FBS (10%); PEN [10,000 U/mL]/STR [10,000 μg/mL] (2%); DEX (1 μM); IBMX (0.5 M); IND (200 μM); INS (10 μg/mL) | Total RNA | Microarray | ||
| NA | 7, 14 | MEM-α; FBS (10%); AMPI (100 U/mL); STR (0.1 mg/ml); DEX (1 × 10–7 M); IBMX (0.5 mM); IND (50 mM); bFGF (1ng/mL); UltraGlutamine (2 mM) | Total RNA (ST-DGE) and miRNA (RNA-Seq) | ST-DGE and RNA-Seq (Illumina HiSeq 2000) | ||
| NA | 3 | hMSC Adipogenic Differentiation Bullet Kit (Lonza) | Total and polysome-associated RNA | RNA-Seq (SOLiD4 System) | ||
| NA | 1, 7, 14, 21 | H-DMEM; FBS (10%); ascorbic acid (5 μg/mL); DEX (1 × 10–7 mol/L); IBMX (0.5 mmol/L) | mRNA and miRNA | Microarray | ||
| CD29+ | 3 | L-DMEM; FBS (10%); DEX (10–7 M); IND (50 ug/ml); IBMX (0.45 mM); ascorbate-2 phosphate (50 μg/ml); INS (0.01 mg/ml) | Total RNA | Microarray | ||
| NA | 0, 1, 3, 5, 7 | Medium 199; FBS (10%); PEN/STR (1%); DEX (1 μM); IND (200 μM); INS (10 μg/mL); methylxanthine (0.5 mM) | Total RNA | RNA-Seq (Illumina HiSeq 2500) | ||
| NA | 3 | DMEM-F12; FBS (15%); PEN (100 U/mL); STR (100 μg/mL); DEX (1 μM); IBMX (500 μM); IND (200 μM); INS (1 μg/mL) | Total and polysome-associated RNA (Ribosome Profiling) | RNA-Seq (SOLiD4 System) | ||
| CD44+ | 0, 1, 3, 7, 17 | DMEM; glucose (4.5 g/L); FBS (10%); DEX (1μM); IND (0.2 mM); IBMX (0.5 mM); INS (10 μg/ml) | Total RNA | Microarray | ||
| NA | 15 | DMEM; FBS (10%); DX (1 μM); IBMX (0.5 mM); INS (1 μg/ml) | Total RNA | RNA-Seq single cell | ||
| NA | 1, 3, 5, 7, 9, 14 | H-DMEM; FBS (10%); DEX (1 μM); IND (0.2 mM); IBMX (0.5 mM); INS (0.01 mg/ml) | Total RNA | Microarray | ||
| NA | 0, 1, 7, 14, 21 | MEM-α; FBS (20%); PEN (100 U/ml); STR (100 μg/ml); L-glutamine (2 mM); DEX (0.5 μM); IBMX (0.5 mM); IND (50 μM) | Total RNA | Microarray | ||
| CD44+ | 0, 14 | MEM-α; FBS (10%); DEX (1 μM); IBMX (0.5 mM); IND (100 μg/mL); INS (0.01 mg/ml) | Total RNA | Microarray | ||
| NA | 7, 14, 21, 28 | MEM-α; FBS (10%); DEX (1 μM); IBMX (0.5 mM); INS (0.01 mg/ml) | Total RNA | RNA-Seq (Ion) | ||
| NA | 0, 7, 14, 21, 28 | hMSC Basal Medium (Cyagen); DEX (1.0 μM); IBMX (0.5 mM); INS (0.01 mg/ml) | Total RNA | RNA-Seq (Ion) | ||
| NA | 0, 7, 14, 21, 28 | hMSC basal medium (Cyagen); DEX (1.0 μM); IBMX (0.5 mM); INS (0.01 mg/ml) | miRNA | RNA-Seq (Ion) | ||
| NA | 0, 7, 14, 21, 28 | MEM-α; FBS (10%); DEX (1 μM); IBMX (0.5 mM); INS (0.01 mg/ml) | Total RNA | RNA-Seq (Ion) | ||
| NA | 0, 3, 8 | DMEM/Ham’s F12; DEX (1 μM); IBMX (100 μM); INS (0.86 μM); rosiglitazone (1 μM); transferrin (10 μg/ml); triiodothyronine (0.2 nM) | small RNAs | RNA-Seq (SOLiD) | ||
| NA | Differentiation: 0, ∼10; Mineralization: ∼24 | Differentiation: MEM-α; FBS (10%); PEN (100 U/mL); STR (0.1 mg/mL); ascorbic acid-2 phosphate (0.1 M); DEX (10–8 M) Mineralization: + BGP (10 mM) | Total RNA (miRNA) | Microarray | ||
| CD73+ | 0, 28 | DMEM; FBS (10%); DEX (0.1 mol/L); BGP (10 mmol/L); ascorbic acid-2-phosphate (50 g/mL) | Total RNA | Microarray | ||
| NA | 0, 0.25, 0.5, 1, 3, 7, 10, 13 | MEM; FBS (10%); PEN/STR (1%); DEX (10 nM); l-ascorbic acid (0.2 mM); BGP (10mM); 1,25-dihydroxyvitamin D3 (10 mM) | miRNA | RNA-Seq (Illumina HiSeq 2000) | ||
| CD73+ | 0, 21 | DMEM; glucose (4.5 g/L); FCS (10%); antibiotics (1 %); DEX (1 x 10–7 M); ascorbic acid (50 μg/mL) | Total RNA | Microarray | ||
| CD29+ (>95%) | 0, 4, 6 | L-DMEM; FBS (10%); ascorbate-2-phosphate (50 μM); BGP (10 mM); DEX (0.1 μM); PEN (100 U/ml); STR (100 g/ml) | Total RNA | Microarray | ||
| CD29+ (>70%) | 14 | BGP (10 mM); L-ascorbic acid (50 mM); DEX (100 nM) | Total RNA (miRNA) | Microarray | ||
| Four days after seeding: | Differentiation: 0, ∼5.5, ∼10.5, ∼24.2; Mineralization: ∼17.5, ∼23.6, ∼30.7 | Differentiation: MEM-α; FBS (10%); PEN (100 U/mL); STR (0.1 mg/mL); ascorbic acid-2 phosphate (100 μM); DEX (10–8 M) Mineralization: BGP (10 mM) | Total RNA | Microarray | ||
| STRO-1+ | 7 | DEX (10 nM), BGP (10 mM) and vitamin C (50 μg/ml). | Total RNA (lncRNA, circRNA, mRNA) | RNA-Seq (Illumina HiSeq2000) | ||
| NA | 1, 3, 7 | with or without 10–7M DEX | Total RNA | Microarray | ||
| NA | 0, 14 | OriCell human ASC Osteogenic Differentiation Medium (Cyagen) | Total RNA (lncRNA, mRNA) | Microarray | ||
| CD44+ | 0,14 | BGP (10 mM); ascorbic acid (50 mM); DEX (100 nM) | Total RNA | Microarray | ||
| CD44+ | 4, 7, 14, 21 | DMEM; FBS (10%); PEN (100 U/ml); STR (100 μg/ml); L-glutamine (2 mM); DEX (10 nM); ascorbic-acid-2-phosphate (0.1 mM); BGP (10 mM) | Total RNA | Microarray | ||
| NA | 28 | MEM-α; FBS (10%); ascorbic acid 2-phosphate (100 μmol/L); KH2PO4 (2.8 mmol/L); DEX sodium phosphate (1 × 10–7 mol/l); HEPES (20 mmol/L) | Total RNA | Microarray | ||
| CD29+ | 4,14 | MEM-α; FBS (10%); PEN (100 U/mL); STR (100 mg/mL); L-ascorbic acid phosphate magnesium salt (82 μg/mL); BGP (10 mmol/L); DEX (10 nmol/L) | Total RNA | RNA-Seq (SOLiD System) | ||
| NA | 21 | StromaQual; FBS (10%); BGP (10 mM); L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate (50 μg/ml); DEX (10 nM); 1% antibiotic | Total RNA | RNA-Seq (Ion Proton) | ||
| NA | 0, 0.25, 0.5, 1, 3, 6, 9,12 | MEM; FCS (10%); PEN/STR (1%); BGP (10 mM); L-ascorbic acid (50 μg/mL); DEX (10 nM); calcitriol (1,25-dihydroxyvitamin D3) (10 nM) | Total RNA | RNA-Seq (Illumina HiSeq 2000) | ||
| NA | 7 | STEMPRO osteogenesis differentiation Kit (Invitrogen) | Total RNA (lncRNA, mRNA) | Microarray | ||
| NA | 0, 7 | MEM-α; FBS (10%); antibiotics (1%); DEX (100 nM); ascorbic acid (0.2 mM); BGP (10 mM) | Total RNA (circRNA, mRNA, miRNA) | Microarray | ||
| CD73+ | 0, 3, 7, 14 | MEM-α; FBS (10%); PEN/STR (1%); DEX (100 nM); L-ascorbic acid (200 μM); BGP (10 mM) | Total RNA (circRNA, mRNA) and miRNA | RNA-Seq (HiSeq 2000, Illumina) | ||
| NA | 21 | BMP-2-conditioned medium obtained after incubation of chondrogenic medium [DMEM; DEX (0.1 μM); ascorbic acid (0.17 mM); ITS supplement (1%) (Sigma)] on confluent C9 cells for 48 hours | Total RNA | Microarray | ||
| NA | 3 | H-DMEM; FBS (2%); DEX (100 nM); L-ascorbic acid-2 phosphate (50 mM); BD ITS+ Premix (1:100); TGF beta-3 (10 ng/mL) | Total RNA | Microarray | ||
| CD44+ (>97%) | 0, 1, 3, 7, 14, 21 | H-DMEM; PEN/STR (1%); ITS+ Premix (Corning) (1%); DEX (100 nM); ascorbic acid (50 μg/mL); L-proline (40 μg/ml); recombinant human TGF beta 3 (rhTGF-b3) (10 ng/ml) | Total RNA | RNA-Seq (HiSeq 2500, Illumina) | ||
| NA | 14 | Chondrocyte Differentiation Medium Single Quotes Kit CC-4408 (Cambrex) | Total RNA | Microarray | ||
| NA | 0, 3, 7, 10, 14, 21, 28 | H-DMEM; ITS+ (1%); DEX (10–7 M); sodium pyruvate (1 mM); ascorbic acid-2 phosphate (120 mM); non-essential amino acids (100 mM); TGF beta-1 (10 ng/mL) | Total RNA | Microarray | ||
| CD73+ | 1 | (Adi) hMSC Adipogenic Differentiation Medium (hMSC Adipogenic Bullet kit, Lonza) (Ost) hMSC Osteogenic Differentiation Medium (hMSC Osteogenic Bullet kit, Lonza) | Total and polysome-associated RNA | RNA-Seq (Illumina HiSeq 2500) | ||
| NA | -2, 0, 0.33, 2, 5, 10, 15 | (Adi) DMEM/Ham’s F12; transferrin (10 μg/ml); INS (0.86 μM); triiodothyronine (0.2 nM); DEX (1 μM); IBMX (100 μM); rosiglitazone (100 nM) (Ost) MEM-α; FCS (10%); L-ascorbic acid phosphate (50 μg/ml); BGP (10 mM); DEX (100 nM) | Total RNA | Microarray | ||
| CD44+ (100%) | 7 | (Cho) DMEM; glucose (4.5 g/L); PEN (100 U/mL); STR (100 μg/mL); ITS+ Premix (Corning) (1%); non-essential amino acids (1%); ascorbic acid 2-phosphate (50 μg/mL); DEX (100 nM); TGF beta-1 (10 ng/mL) (Ost) DMEM; glucose (1 g/L); FBS (10%); PEN (100 U/mL); STR (100 μg/mL); ascorbic acid 2-phosphate (50 μg/mL); BGP (5 mM); DEX (10 nM) | Total RNA (RNA-Seq, miRNA and piRNA) and circRNA (Microarray) | RNA-Seq (Illumina NextSeq500) and microarray | ||
| CD73+ | 0, 1, 2, 3, 4, 5, 6, 7 | (Adi) DEX (1 μM); IBMX (500 μM); IND (100 μM); INS (10 μg/ml) (Cho) INS (6.25 μg/ml); L-ascorbic acid 2-phosphate (50 μM); TGF beta-1 (10 ng/mL) (Ost) DEX (100 nM); L-ascorbic acid 2-phosphate (50 μM); BGP (10 mM) | Total RNA | RNA-Seq | ||
| NA | 0, 1, 3, 7 and 21 | (Adi) DMEM-F12; newborn calf serum (5%); DEX (1 μM); IBMX (50 μM); IND (60 μM) (Cho) DMEM; DEX (0.1 μM); ascorbate-2 phosphate (0.17 mM); insulin-transferrin-sodium selenite supplement (1%); TGF beta-3 (10 ng/mL) or BMP-2 (100 ng/mL) (Ost) H-DMEM; FCS (10%); BGP (10 mM); DEX (0.1 μM); ascorbic acid (0.05 mM) | Total RNA | Microarray | ||
FIGURE 1Different transcriptomic approaches to study gene expression profile during adipogenic, chondrogenic and osteogenic differentiation of MSC. The scheme summarizes the studies explored in this review, which used adipose tissue, bone marrow and dental pulp as sources for MSC isolation and performed different induction protocols. Different RNA types were analyzed, as mRNA (by total mRNA, polysome profiling and/or ribosome footprint profiling analysis), microRNA (miRNA), long non-coding RNA (lncRNA) and circular RNA (circRNA). These strategies allow the characterization of main processes, pathways and key factors regulated during the differentiation time course that improve our knowledge regarding osteogenesis, chondrogenesis and adipogenesis.